Artiva Biotherapeutics (NASDAQ:ARTV) Director Ra Capital Management, L.P. Acquires 391,019 Shares of Stock

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Director Ra Capital Management, L.P. purchased 391,019 shares of the firm’s stock in a transaction dated Friday, June 12th. The stock was acquired at an average cost of $8.57 per share, with a total value of $3,351,032.83. Following the completion of the acquisition, the director directly owned 16,622,736 shares in the company, valued at approximately $142,456,847.52. This trade represents a 2.41% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Ra Capital Management, L.P. also recently made the following trade(s):

• On Tuesday, June 16th, Ra Capital Management, L.P. purchased 124,893 shares of Artiva Biotherapeutics stock. The stock was acquired at an average cost of $8.89 per share, with a total value of $1,110,298.77.
• On Monday, June 15th, Ra Capital Management, L.P. purchased 15,414 shares of Artiva Biotherapeutics stock. The stock was acquired at an average cost of $8.99 per share, with a total value of $138,571.86.
• On Thursday, June 11th, Ra Capital Management, L.P. purchased 548,580 shares of Artiva Biotherapeutics stock. The stock was acquired at an average cost of $7.91 per share, with a total value of $4,339,267.80.
• On Wednesday, June 10th, Ra Capital Management, L.P. purchased 103 shares of Artiva Biotherapeutics stock. The stock was acquired at an average cost of $7.00 per share, with a total value of $721.00.
• On Tuesday, June 9th, Ra Capital Management, L.P. purchased 479,039 shares of Artiva Biotherapeutics stock. The stock was acquired at an average cost of $6.91 per share, with a total value of $3,310,159.49.
• On Monday, May 11th, Ra Capital Management, L.P. purchased 6,510,416 shares of Artiva Biotherapeutics stock. The stock was acquired at an average cost of $11.52 per share, with a total value of $74,999,992.32.

Artiva Biotherapeutics Stock Performance

NASDAQ ARTV opened at $8.91 on Wednesday. Artiva Biotherapeutics, Inc. has a one year low of $1.47 and a one year high of $14.53. The company has a 50-day simple moving average of $9.02 and a 200-day simple moving average of $6.23. The firm has a market capitalization of $220.26 million, a PE ratio of -2.52 and a beta of 2.38.

Artiva Biotherapeutics (NASDAQ:ARTV) last posted its quarterly earnings results on Friday, May 8th. The company reported ($0.95) EPS for the quarter, missing the consensus estimate of ($0.88) by ($0.07). Equities analysts forecast that Artiva Biotherapeutics, Inc. will post -2.45 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Prelude Capital Management LLC bought a new stake in shares of Artiva Biotherapeutics during the 3rd quarter worth about $41,000. Bank of America Corp DE raised its position in shares of Artiva Biotherapeutics by 225.8% during the 3rd quarter. Bank of America Corp DE now owns 16,145 shares of the company’s stock worth $46,000 after buying an additional 11,190 shares in the last quarter. Dimensional Fund Advisors LP bought a new stake in shares of Artiva Biotherapeutics during the 1st quarter worth about $131,000. OMERS ADMINISTRATION Corp bought a new stake in shares of Artiva Biotherapeutics during the 4th quarter worth about $91,000. Finally, Sanctuary Advisors LLC bought a new stake in shares of Artiva Biotherapeutics during the 1st quarter worth about $139,000.

Analysts Set New Price Targets

A number of research firms have issued reports on ARTV. Wall Street Zen lowered shares of Artiva Biotherapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, May 17th. HC Wainwright boosted their target price on shares of Artiva Biotherapeutics from $15.00 to $35.00 and gave the company a “buy” rating in a research note on Friday, May 8th. Cantor Fitzgerald reissued an “overweight” rating on shares of Artiva Biotherapeutics in a research note on Tuesday, May 26th. Weiss Ratings reissued a “sell (d-)” rating on shares of Artiva Biotherapeutics in a research note on Friday, April 24th. Finally, Wedbush boosted their target price on shares of Artiva Biotherapeutics from $23.00 to $40.00 and gave the company an “outperform” rating in a research note on Monday, May 11th. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $39.00.

About Artiva Biotherapeutics

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company’s proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva’s pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.